# ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

> **NCT05116761** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Direct Biologics, LLC**

## Conditions studied

- Covid19
- Postviral Syndrome
- Dyspnea

## Interventions

- **BIOLOGICAL:** Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT05116761
- **Lead sponsor:** Direct Biologics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11
- **Primary completion:** 2024-11
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study no longer part of development plan.
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116761, "ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05116761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*